The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes
Abstract
BACKGROUND: An effective prophylactic vaccine would help control the spread of genital herpes. METHODS: We conducted two double-blind, randomized trials of a herpes simplex virus type 2 (HSV-2) glycoprotein-D-subunit vaccine with alum and 3-O-deacylated-monophosphoryl lipid A in subjects whose regular sexual partners had a history of genital herpes. In Study 1, subjects were seronegative for herpes simplex virus type 1 (HSV-1) and HSV-2; in Study 2, subjects were of any HSV serologic status. At months 0, 1, and 6, subjects received either vaccine or a control injection and were evaluated for 19 months. The primary end point was the occurrence of genital herpes disease in all subjects in Study 1 and in HSV-2-seronegative female subjects in Study 2. RESULTS: A total of 847 subjects who were seronegative for both HSV-1 and HSV-2 (268 of them women, in Study 1) and 1867 subjects who were seronegative for HSV-2 (710 of them women, in Study 2) underwent randomization and received injections. Vaccination was well tolerated and elicited humoral and cellular responses. Overall, the efficacy of the vaccine was 38 percent in Study 1 (95 percent confidence interval, -18 to 68 percent; 15 cases occurred in the vaccine group and 24 in the control group), and efficacy in female subjects was 42 percent in Study 2 (95 percent confidence interval, -31 to 74 percent; 9 cases occurred in the vaccine group and 16 in the control group). In both studies, further analysis showed that the vaccine was efficacious in women who were seronegative for both HSV-1 and HSV-2: efficacy in Study 1 was 73 percent (95 percent confidence interval, 19 to 91 percent; P=0.01), and efficacy in Study 2 was 74 percent (95 percent confidence interval, 9 to 93 percent; P=0.02). It was not efficacious in women who were seropositive for HSV-1 and seronegative for HSV-2 at base line or in men. CONCLUSIONS: These studies suggest that the glycoprotein D vaccine has efficacy against genital herpes in women who are seronegative for both HSV-1 and HSV-2 at base line but not in those who are seropositive for HSV-1 and seronegative for HSV-2. It had no efficacy in men, regardless of their HSV serologic status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Herpes Simplex Virus Type 2 in the United States, 1976 to 1994
Fleming, D. T., McQuillan, G. M., Johnson, R. E., Nahmias, A. J., Aral, S. O., Lee, F. K., & St. Louis, M. E. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710163371601 · Cited by 1,189
A Gender Gap in Autoimmunity: Task Force on Gender, Multiple Sclerosis and Autoimmunity
Whitacre, C. C., Reingold, S. C., O'Looney, P. A., Blankenhorn, E., Brinley, F., Collier, E., Duquette, P., Fox, H., Giesser, B., Gilmore, W., et al. (1999) · Science · doi:10.1126/science.283.5406.1277 · Cited by 851
Infections with Herpes Simplex Viruses
Corey, L., & Spear, P. G. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603133141105 · Cited by 778
A Prospective Study of New Infections with Herpes Simplex Virus Type 1 and Type 2
Langenberg, A. G. M., Corey, L., Ashley, R. L., Leong, W. P., & Straus, S. E. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911043411904 · Cited by 510
Corey, L., Langenberg, A. G. M., Ashley, R., Sekulovich, R. E., Izu, A. E., Douglas, Jr., Handsfield, H. H., Warren, T., Marr, L., Tyring, S., et al. (1999) · JAMA · doi:10.1001/jama.282.4.331 · Cited by 490
Self-citationInfections with Herpes Simplex Viruses
Corey, L., & Spear, P. G. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603203141205 · Cited by 379
Underdiagnosis of Genital Herpes by Current Clinical and Viral-Isolation Procedures
Koutsky, L. A., Stevens, C. E., Holmes, K. K., Ashley, R. L., Kiviat, N. B., Critchlow, C. W., & Corey, L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199206043262305 · Cited by 286
Su, Z., & Stevenson, M. M. (2000) · Infection and Immunity · doi:10.1128/iai.68.8.4399-4406.2000 · Cited by 260
Genital Herpes: Review of the Epidemic and Potential Use of Type-Specific Serology
Ashley, R. L., & Wald, A. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.1 · Cited by 222
Prospects for Control of Herpes Simplex Virus Disease through Immunization
Stanberry, L. R., Cunningham, A. L., Mindel, A., Scott, L. L., Spruance, S. L., Aoki, F. Y., & Lacey, C. J. (2000) · Clinical Infectious Diseases · doi:10.1086/313687 · Cited by 200
Self-citation
Cited by
Harper, D. M., Franco, E. L., Wheeler, C., Ferris, D. G., Jenkins, D., Schuind, A., Zahaf, T., Innis, B., Naud, P., De Carvalho, N. S., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17398-4 · Cited by 1,643
Self-citationImpact of sex and gender on COVID-19 outcomes in Europe
Gebhard, C., Regitz-Zagrosek, V., Neuhauser, H. K., Morgan, R., & Klein, S. L. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00304-9 · Cited by 1,306
The X-files in immunity: sex-based differences predispose immune responses
Fish, E. N. (2008) · Nature Reviews Immunology · doi:10.1038/nri2394 · Cited by 1,162
Trends in Herpes Simplex Virus Type 1 and Type 2 Seroprevalence in the United States
Xu, F., Sternberg, M. R., Kottiri, B. J., McQuillan, G. M., Lee, F. K., Nahmias, A. J., Berman, S. M., & Markowitz, L. E. (2006) · JAMA · doi:10.1001/jama.296.8.964 · Cited by 1,035
The rgp120 HIV Vaccine Study Group (2005) · The Journal of Infectious Diseases · doi:10.1086/428404 · Cited by 952
The Xs and Y of immune responses to viral vaccines
Klein, S. L., Jedlicka, A., & Pekosz, A. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70049-9 · Cited by 815
How sex and age affect immune responses, susceptibility to infections, and response to vaccination
Giefing‐Kröll, C., Berger, P., Lepperdinger, G., & Grubeck‐Loebenstein, B. (2015) · Aging Cell · doi:10.1111/acel.12326 · Cited by 761
Once-daily valacyclovir to reduce the risk of transmission of genital herpes.
Corey, L., Wald, A., Patel, R., Sacks, S. L., Tyring, S. K., Warren, T., Douglas, J. M., Paavonen, J., Morrow, R. A., Beutner, K. R., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035144 · Cited by 720
Self-citationWhitley, R. J., & Roizman, B. (2002) · Wiley Encyclopedia of Molecular Medicine · doi:10.1002/0471203076.emm0597 · Cited by 700
Gupta, R., Warren, T., & Wald, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61908-4 · Cited by 599
Fatahzadeh, M., & Schwartz, R. A. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.06.027 · Cited by 570
Efficacy Results of a Trial of a Herpes Simplex Vaccine
Belshe, R. B., Leone, P. A., Bernstein, D. I., Wald, A., Levin, M. J., Stapleton, J. T., Gorfinkel, I., Morrow, R. L. A., Ewell, M. G., Stokes-Riner, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1103151 · Cited by 510
Self-citationSex and Gender Differences in the Outcomes of Vaccination over the Life Course
Flanagan, K. L., Fink, A. L., Plebanski, M., & Klein, S. L. (2017) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100616-060718 · Cited by 508
Steinhagen, F., Kinjo, T., Bode, C., & Klinman, D. M. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.08.002 · Cited by 501
GIANNINI, S., HANON, E., MORIS, P., VANMECHELEN, M., MOREL, S., DESSY, F., FOURNEAU, M., COLAU, B., SUZICH, J., & LOSONKSY, G. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.06.005 · Cited by 496
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives
Garçon, N., Chomez, P., & Van Mechelen, M. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.723 · Cited by 476
Till, S. J., Francis, J. N., Nouri-Aria, K., & Durham, S. R. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.03.024 · Cited by 434
Seroprevalence of Herpes Simplex Virus Types 1 and 2--United States, 1999-2010
Bradley, H., Markowitz, L. E., Gibson, T., & McQuillan, G. M. (2014) · Journal of Infectious Diseases · doi:10.1093/infdis/jit458 · Cited by 432
Prophylactic human papillomavirus vaccines
Lowy, D. R. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28607 · Cited by 428
Neonatal Herpes Simplex Infection
Kimberlin, D. W. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.1.1-13.2004 · Cited by 416
Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems
Garçon, N., & Van Mechelen, M. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.29 · Cited by 314
Mayaud, P. (2004) · Sexually Transmitted Infections · doi:10.1136/sti.2002.004101 · Cited by 311
Unmet needs in modern vaccinology
Leroux-Roels, G. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.07.021 · Cited by 304
Klein, S. L. (2012) · BioEssays · doi:10.1002/bies.201200099 · Cited by 284
Understanding and learning from the success of prophylactic human papillomavirus vaccines
Schiller, J. T., & Lowy, D. R. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2872 · Cited by 293
Global control of sexually transmitted infections
Low, N., Broutet, N., Adu-Sarkodie, Y., Barton, P., Hossain, M., & Hawkes, S. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69482-8 · Cited by 279
Toll‐like receptors: the swiss army knife of immunity and vaccine development
Dowling, J. K., & Mansell, A. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.22 · Cited by 273
Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward
Padian, N. S., Buvé, A., Balkus, J., Serwadda, D., & Cates, W. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60885-5 · Cited by 264
Recent Progress in Herpes Simplex Virus Immunobiology and Vaccine Research
Koelle, D. M., & Corey, L. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.1.96-113.2003 · Cited by 263
Sexual Dimorphism in Innate Immune Responses to Infectious Organisms
Marriott, I., & Huet-Hudson, Y. M. (2006) · Immunologic Research · doi:10.1385/ir:34:3:177 · Cited by 263
Baldridge, J. R., McGowan, P., Evans, J. T., Cluff, C., Mossman, S., Johnson, D., & Persing, D. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.7.1129 · Cited by 256
Lambert, K. C., Curran, E. M., Judy, B. M., Milligan, G. N., Lubahn, D. B., & Estes, D. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.5716 · Cited by 142
Prophylactic and therapeutic implications of toll-like receptor ligands
Hedayat, M., Takeda, K., & Rezaei, N. (2012) · Medicinal Research Reviews · doi:10.1002/med.20214 · Cited by 76
Prevalence and risk factors for infection with herpes simplex virus type-1 and -2 among lesbians.
Marrazzo, J. M., Stine, K., & Wald, A. (2003) · Sexually Transmitted Diseases · doi:10.1097/01.olq.0000091151.52656.e5 · Cited by 69
Carbohydrate Immune Adjuvants in Subunit Vaccines
Bashiri, S., Koirala, P., Toth, I., & Skwarczynski, M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100965 · Cited by 45
A Single Dose of NILV-Based Vaccine Provides Rapid and Durable Protection against Zika Virus
Ku, M. W., Anna, F., Souque, P., Petres, S., Prot, M., Simon-Loriere, E., Charneau, P., & Bourgine, M. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.016 · Cited by 29
Metadata
- Authors
- Stanberry, L. R., Spruance, S. L., Cunningham, A. L., Bernstein, D. I., Mindel, A., Sacks, S., Tyring, S., Aoki, F. Y., Slaoui, M., Denis, M., Vandepapeliere, P., & Dubin, G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-11-21
- Volume
- 347
- Issue
- 21
- Pages
- 1652-1661
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2019840235
- Cited by
- 794
- References
- 26
- FWCI
- 35.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.